-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
Evolving Standards of Care
-
COCOON’s Prophylactic Regimen Resulted in Decreased Incidence and Severity of Dermatologic-related Adverse Events
Industry Supported
The COCOON trial compared SOC with prophylactic management for treatment-related dermatologic events with amivantamab plus lazertinib. In this Q&A, Dr. Martin F. Dietrich explains the prophylactic regimen’s impact on effects of the skin, scalp, and nails. APP Alyson Singer offers best practices for patient education.
-
CheckMate 568: Efficacy and Biomarker Analysis for Nivolumab and Ipilimumab in NSCLC
By Neal Ready, MD, PhD Posted: February 12, 2020 Dr. Neal Ready Programmed death receptor (PD-1) checkpoint monoclonal antibody therapy has proven a major advancement in the management of advanced NSCLC, with prolonged duration of response and significant 5-year survival rates not seen with combination platinum-based chemotherapy.1-6 CheckMate 012, CheckMate 568, and CheckMate 227 are…
-
Smoking Ban in Austria Passed After Years of Political Wrangling
Posted: February 12, 2020 November 1, 2019—After years of political volleying and public outcry, Austria implemented a full indoor smoking ban in bars, cafes, and restaurants. With its capitol, Vienna, consistently being voted “the most livable city in the world” according to an index compiled by the Economist Intelligence Unit,1 the decrease in Austria’s smoking…
-
Novel Insights on ctDNA Dynamics During Targeted Therapy and Immune Checkpoint Blockage in NSCLC
By Christian Rolfo, MD, PhD, MBA, Dr.h.c. Posted: December 11, 2019 IN REFERENCE TO: Phallen J, Leal A, Woodward BD, et al. Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer. Cancer Res. 2019;79(6):1204-1213. Anagnostou V, Forde PM, White JR, et al. Dynamics of Tumor and Immune Responses during Immune Checkpoint…
-
Lung Cancer Leading the Charge for Tumor-Agnostic Targeted Therapies
By Robert C. Doebele, MD, PhD Posted: December 11, 2019 Dr. Robert C. Doebele Early in the drug development of targeted therapies, specific oncogene mutations were often associated with a single disease: HER2 gene amplification with breast cancer, BCR-ABL fusions with chronic myelogenous leukemia, EGFR mutations with lung cancer, and BRAF mutations with melanoma. Thus,…
-
Experts Discuss Turnaround Times, Geographic Differences Regarding Liquid Biopsy
Improved Turnaround Times for Biopsy Results Matters More Than Type of Biopsy By Dr. Edgardo S. Santos Castillero, MD, FACP Posted: December 11, 2019 Dr. Edgardo S. Santos Castillero Regarding “Liquid Biopsy for Assessing Response or Progression in Advanced NSCLC” by Dr. Geoffrey R. Oxnard published in the October issue of the IASLC Lung Cancer News, I…
-
Concurrent Chemoradiation Followed by Consolidation Therapy: Questions Remain Despite Transformational Data
Posted: November 12, 2019 Now that data from the PACIFIC trial have been incorporated into daily practice, similar trials are validating the results or taking PACIFIC data in new directions. Greg Durm, MD, is a medical oncologist at the Indiana University Simon Cancer Center and principal investigator of a phase II trial examining concurrent chemoradiation…
-
Key Findings from the CAR T-Cell Study Presented at the 2019 AACR Annual Meeting
By Prasad S. Adusumilli, MD, FACS, FCCP Posted: November 12, 2019 My colleagues and I conducted a phase I clinical trial of mesothelin-targeted chimeric antigen receptor (CAR) T-cell therapy in patients with malignant pleural disease from mesothelioma and metastatic lung or breast cancer, and we presented the findings at the 2019 American Association for Cancer…
-
Adjuvant EGFR-TKI for Resected NSCLC: Who, When, and Where?
By Si-Yang Liu, MD, and Yi-Long Wu, MD Posted: November 12, 2019 Dr. Si-Yang Liu Dr. Yi-Long Wu In the twentieth century, adjuvant chemotherapy became the standard of care for resected NSCLC based on several clinical trials including IALT, JBR.10, ANITA, and a meta-analysis of individual patient data from the LACE trial. Adjuvant chemotherapy increased…
-
Antibody–Drug Conjugates in NSCLC: Complexities, Challenges, and Potential
By David E. Gerber, MD Posted: November 12, 2019 Dr. David E. Gerber The underlying concept for antibody–drug conjugates (ADCs) is relatively straightforward: capitalize on the highly specific targeting of monoclonal antibodies to convey a lethal payload to cancer cells while minimizing exposure of normal tissues. However, after more than 20 years of clinical development,…
-
Consolidating Gains with Chemotherapy in SCLC Maintenance Trials: A Discussion with Dr. Shirish Gadgeel
Posted: August 14, 2019 Shirish Gadgeel, MBBS, is the Mary Lou Kennedy Research Professor in Thoracic Oncology and a professor in the Division of Hematology/Oncology at the University of Michigan Rogel Cancer Center. He is the co-leader of the Thoracic Oncology Research Program and associate director for cancer care at Networking and Affiliated Centers. In an…
View ILCN Archives
Provider Resources
Popular Articles